http://dx
Rotterdam criteriaebased diagnostic subtype is not a strong predictor of cutaneous phenotype in patients with polycystic ovary syndrome: A crosssectional study
To the Editor: Polycystic ovary syndrome (PCOS) has historically been associated with prominent skin findings, including hirsutism, acanthosis nigricans (AN), acne, and androgenic alopecia (AGA), as well as systemic findings. The Rotterdam PCOS diagnostic criteria require 2 of 3 features-biochemical or clinical hyperandrogenism (HA), oligoanovulation (OA), and polycystic ovaries (PCO) 1 -resulting in 4 PCOS diagnostic subtypes (Table I) . Whether PCOS subtypes have distinct skin findings and cardiometabolic profiles is poorly understood. The clinical significance and long-term prognosis of these subtypes remain controversial.
We performed a cross-sectional study of a cohort of 255 women meeting the Rotterdam criteria for PCOS to determine skin and metabolic phenotypes among different PCOS subtypes. HA was defined by cutaneous presentation (hirsutism) or biochemical HA (ie, elevated androgens). The prevalence of skin findings among PCOS subtypes was strikingly similar (Table I) . This remained true, even for hirsutism, when PCOS subtypes were defined by biochemical HA alone rather than biochemical HA or hirsutism (data not shown). Older age mitigates the cutaneous phenotype in PCOS 2 ; there were no significant differences in age among subtypes (data not shown). There was a trend toward reduced prevalence of AN in the OA 1 PCO subtype (ie, patients lacking evidence of hyperandrogenism) but no significant differences in other skin findings.
Metabolic phenotype, specifically cardiometabolic risk profile, was not differentially associated with PCOS subtypes (data not shown). However, as previously observed, 3, 4 the OA 1 PCO subtype had a nonsignificant trend toward a more favorable cardiometabolic profile, including improved lipid markers and reduced insulin resistance.
Because PCOS subtypes did not strongly differ in their skin findings or cardiometabolic risk profiles, we examined the effects of biochemical HA and obesity on clinical phenotype. Biochemical HA and obesity were not associated with one another ( 2 ; P ¼ .90, data not shown). Body mass index was similar among PCOS subtypes (data not shown). Obesity was significantly associated with metabolic abnormalities and increased cutaneous findings, specifically hirsutism, AN, and AGA (Table II) . Biochemical HA was associated with a trend in certain metabolic and cutaneous abnormalities (AN). The association of AN with both biochemical HA and obesity corroborates data suggesting that AN may indicate increased clinical severity among women with PCOS. 5 Hirsutism, acne, and AGA were not associated with a pooled measure of biochemical HA (Table II) . However, the association between free testosterone alone and hirsutism has been previously reported. 5 This likely reflects a stronger association between free testosterone and cutaneous HA than exists for other androgens.
PCOS subtypes are not strong predictors of cutaneous or metabolic phenotype; the role of hyperandrogenism as an independent phenotypic determinant remains unclear. Indeed, these and other 3, 4 findings challenge whether OA 1 PCO should be considered a subtype of PCOS given its milder phenotype. In addition, while obesity is not a J AM ACAD DERMATOL criterion for PCOS, these data suggest that increased body mass index is an important correlate of both skin findings and cardiometabolic risk in patients with PCOS. Targeting obesity may therefore be a critical intervention in PCOS care. Longitudinal follow-up will help validate the value of PCOS subtypes and other phenotypic characteristics in prognosticating cardiometabolic risk. Biochemical HA was defined as elevation of testosterone, free testosterone, DHEAS, or androstenedione. Two-hour (2-hr) oral glucose tolerance testing was done with 75 g of glucose. Hirsutism was defined by modified FerrimaneGallwey score [7. To test the null hypotheses that the distributions of the metabolic measurements in women classified by biochemical HA or BMI status were the same, the ManneWhitney U test was used. To test the null hypothesis that prevalence of each skin finding was independent of biochemical HA or BMI statuses, the 2 test was used. BMI, Body mass index; HA, hyperandrogenism; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment of insulin resistance.
Risk of Alzheimer's disease is not increased among patients with hidradenitis suppurativa: A retrospective population-based cohort analysis To the Editor: Familial hidradenitis suppurativa (HS) and Alzheimer's disease (AD) have been linked to mutations in the -secretase complex. 1 In the brain, -secretase cleaves amyloid precursor protein, which results in the development of -amyloid plaques responsible for the development of AD. Genetic inactivation of -secretase in mouse skin also produces epidermal and follicular histologic abnormalities resembling those in HS that are thought to arise from alterations in Notch signaling. 2 Gamma secretase was also established as the genetic basis of disease for a subset of familial HS. 1 Given these genetic links, we evaluated the association between HS and AD in a retrospective cohort study. We used a data analytics and research platform that sources clinical data from 27 health systems mapped to the single set of Unified Medical Language System ontologies to create longitudinal records for a heterogeneous group of [48 million unique patients in the United States. 3 The Systematized Nomenclature of Medicine-Clinical Terms ''hidradenitis'' and ''Alzheimer's disease,'' which have one-to-one mapping with the International Classification of Diseases, 9th revision codes for HS (705.83) and AD (331.0), were used to identify patients. This methodology has been validated previously for both conditions. 4, 5 The study population included all patients with an active status in the database within the past 5 years and nonmissing sex and race information. Patients \40 years of age were excluded, given the rarity of AD in persons under this age. To ensure that our analysis captured individuals with newly diagnosed AD, patients with a diagnosis of AD before to the study start date were excluded. In addition, patients with an HS diagnosis occurring after a diagnosis of AD were excluded to ensure that the exposure of interest occurred before the outcome. The primary outcome of interest was diagnosis of AD. Age and sex were included as covariates. We obtained populationlevel counts of the number of patients with a firstever diagnosis of AD between 2012 and 2016 for each combination of categorical predictor variables (HS status, age, and sex). We also recorded groupspecific counts of patients with no AD diagnosis during the study period.
The characteristics of the HS cohort are described in Table I . There were 28,755 patients with HS identified. The absolute risk of AD among patients with HS was 0.2% (65/27, 755). In crude analysis, HS was associated with a decreased risk of AD (odds ratio ¼ 0.34 [95% confidence interval {CI}, 0.26-0.43], P \ .0001). After adjusting for age and sex, HS was associated with a modest, though statistically insignificant, increase in the risk of AD (OR ¼ 1.23 [95% CI, 0.96-1.56], P ¼ .11). Theut Riis et al 6 also evaluated the relationship between HS
